Organization | Foundation for a Smoke-Free World

Foundation for a Smoke-Free World Report issue

Foundation Phase 2 Phase 3 Phase 4

Founded: New York NY United States (2017)

Organization Overview

First Clinical Trial

2019

NCT04188106

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Foundation for a Smoke-Free World | Foundation for a Smoke Free World INC

Active Ingredients

Drugs in Phase 4 Trials (2)

hydroxyzine (vistaril) (1 trial)

varenicline (chantix) (2 trials)

Drugs in Phase 3 Trials (4)

bupropion (wellbutrin) (2 trials)

emb-01 (1 trial)

nicotine (nicorette) (5 trials)

zonisamide (Zonegran) (2 trials)

Drugs in Phase 2 Trials (3)

cycloserine (seromycin) (1 trial)

metyrapone (metopirone) (1 trial)

oxazepam (serax) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Dyssomnias (Phase 4)

Parasomnias (Phase 4)

Sleep Wake Disorders (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 12
# of Trial APIs: 9